Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease

Secretase-Independent and RhoGTPase/PAK/ERK-Dependent Regulation of Cytoskeleton Dynamics in Astrocytes by NSAIDs and Derivatives

(2017) Mathieu P. Lichtenstein et al.   JOURNAL OF ALZHEIMERS DISEASE

Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors

(2016) Genevieve Evin   BIODRUGS

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

(2016) Susanna Eketjäll et al.   JOURNAL OF ALZHEIMERS DISEASE

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates

(2016) Mihirbaran Mandal et al.   JOURNAL OF MEDICINAL CHEMISTRY

Alzheimer Disease

(2016) Mark E. Jentoft et al.   MAYO CLINIC PROCEEDINGS

Endogenous APP accumulates in synapses after BACE1 inhibition

(2016) Saket Milind Nigam et al.   NEUROSCIENCE RESEARCH

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

(2016) Francesco Panza et al.   Biomed Research International

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

(2015) Adam C. Kaufman et al.   ANNALS OF NEUROLOGY

Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer’s Disease

(2015) Arun K. Ghosh et al.   ChemMedChem

Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance

(2015) Arnold Bakker et al.   NeuroImage-Clinical

Effects of oral ELND005 (scyllo-inositol) on neuropsychiatric symptoms in a 78-week phase 2 study in mild/moderate Alzheimer's disease (AD): Potential role of myo-inositol reduction

(2014) Constantine Lyketsos et al.   Alzheimers & Dementia

CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609

(2014) Bruce Albala et al.   Alzheimers & Dementia

MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE

(2014) Kina Höglund et al.   Alzheimers & Dementia

Lessons from a Failed γ-Secretase Alzheimer Trial

(2014) Bart De Strooper   CELL

Inhibition of Amyloid-β Aggregation in Alzheimer's Disease

(2014) Qiuming Wang et al.   CURRENT PHARMACEUTICAL DESIGN

AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration

(2014) Robert Alexander et al.   NEUROBIOLOGY OF AGING

Clinical trial of an inhibitor of RAGE-A  interactions in Alzheimer disease

(2014) D. Galasko et al.   NEUROLOGY

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

(2014) Robert Vassar   Alzheimers Research & Therapy

Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF

(2013) Francois Bernier et al.   Alzheimers & Dementia

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice

(2013) Sandra Sivilia et al.   BMC NEUROSCIENCE

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

(2013) Joel Ross et al.   Current Alzheimer Research

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

(2013) Bruce H. Morimoto et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation

(2013) Alex Crowe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

International Work Group Criteria for the Diagnosis of Alzheimer Disease

(2013) Jeffrey L. Cummings et al.   MEDICAL CLINICS OF NORTH AMERICA

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

(2013) Nathan Herrmann et al.   Alzheimers Research & Therapy

Neuropathological Alterations in Alzheimer Disease

(2013) A. Serrano-Pozo et al.   Cold Spring Harbor Perspectives in Medicine

Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo

(2012) Jose A. Morales-Garcia et al.   ACS Chemical Neuroscience

The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration

(2012) Mark Forman et al.   Alzheimers & Dementia

Novel BACE1 inhibitor, E2609, lowers Aβ levels in the brain, cerebrospinal fluid and plasma in rats and guinea pigs

(2012) Tatsuto Fukushima et al.   Alzheimers & Dementia

First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing

(2012) Robert Lai et al.   Alzheimers & Dementia

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome

(2012) Liang-Hao Guo et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice

(2012) Kathryn Rogers et al.   Molecular Neurodegeneration

Drug repositioning for Alzheimer's disease

(2012) Anne Corbett et al.   NATURE REVIEWS DRUG DISCOVERY

Biomarker trajectories across stages of Alzheimer disease

(2012) Giovanni B. Frisoni   Nature Reviews Neurology

Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment

(2012) Arnold Bakker et al.   NEURON

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model

(2012) P. E. Sanchez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose

(2012) Xiao-Jing Sun et al.   Neuroscience Bulletin

Assessment scales in dementia

(2012) Bart Sheehan   Therapeutic Advances in Neurological Disorders

CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects

(2011) M. Ewers et al.   CEREBRAL CORTEX

Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection

(2011) Yi Wen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Unknown

(2011) Daniel Paris et al.   MOLECULAR MEDICINE

Testing the Right Target and Right Drug at the Right Stage

(2011) R. A. Sperling et al.   Science Translational Medicine

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease

(2010) Yakeel T. Quiroz et al.   ANNALS OF NEUROLOGY

Powerful beneficial effects of benfotiamine on cognitive impairment and  -amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice

(2010) X. Pan et al.   BRAIN

Tau in Alzheimer Disease and Related Tauopathies

(2010) K. Iqbal et al.   Current Alzheimer Research

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

(2010) K. R. Brunden et al.   JOURNAL OF NEUROSCIENCE

Neuropathology of Alzheimer's Disease

(2010) Daniel P. Perl   MOUNT SINAI JOURNAL OF MEDICINE

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment

(2010) Michael A. Yassa et al.   NEUROIMAGE

Identifying and validating biomarkers for Alzheimer's disease

(2010) Christian Humpel   TRENDS IN BIOTECHNOLOGY

Defining and labeling disease-modifying treatments for Alzheimer's disease

(2009) Jeffrey L. Cummings   Alzheimers & Dementia

The structure and function of Alzheimer’s gamma secretase enzyme complex

(2009) Sudarsan Krishnaswamy et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

(2009) L. Serenó et al.   NEUROBIOLOGY OF DISEASE

Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment

(2009) Ming Teng Koh et al.   NEUROPSYCHOPHARMACOLOGY

Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice

(2008) Dick Terwel et al.   AMERICAN JOURNAL OF PATHOLOGY

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

(2008) Y. Matsuoka et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS